EUVIMEDEUVIMED entdecken
Crossref

Long‐term outcomes of anti‐thyroid drug treatment in childhood‐onset Graves' disease

Dolrutai Puttawong, Pat Mahachoklertwattana iD, Pawin Numthavaj, Patarawan Woratanarat, Sarunyu Pongratanakul, Peeravit Koad, Preamrudee Poomthavorn iD

Clinical Endocrinology · 2023

DOI: 10.1111/cen.14869 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2023. Verfasst von Dolrutai Puttawong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Antithyroid Agents, Graves Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Outcomes of childhood‐onset Graves' disease (GD) and suggested duration of anti‐thyroid drug (ATD) therapy have been controversial. This study aimed to determine long‐term outcomes following ATD therapy, including remission and relapse rates. Design, patients and measurements A retrospective study of 265 paediatric patients with GD who were initially treated with ATD was conducted. Long‐term outcomes were analysed.

Results

Median (IQR) age at diagnosis was 11.5 (9.4, 13.7) years. Duration of ATD treatment was 4.3 (2.3, 6.7) years and time since diagnosis to the enrolment was 7.1 (3.8, 10.9) years. There were 77, 93 and 95 patients who underwent definitive treatment, had ATD discontinuation, and were still being treated with ATD, respectively. The remission rate was 21% (56 out of 265 patients) and relapse rate was 40% (37 out of 93 patients). Cumulative incidence of first remission increased with the duration of ATD treatment with maximum remission rate at 5.3 years following ATD therapy. Among patients who experienced relapse, approximately 50% had disease relapse which occurred within 1 year after ATD discontinuation. Patients with goitre size of less than 3.5 cm, thyroid‐stimulating hormone receptor antibody of less than 10 IU/L, no ophthalmopathy at diagnosis and methimazole dose requirement of less than 0.25 mg/kg/day at 1 year after treatment were more likely to achieve remission.

Conclusions

Remission rate of childhood‐onset GD was relatively low following ATD treatment. Longer‐term ATD therapy was associated with increased remission rate. Approximately 50% of patients with relapse had disease relapse within 1 year following ATD discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antithyroid AgentsGraves DiseaseHumansChildRetrospective StudiesTreatment OutcomeRemission InductionMethimazoleThyrotropinAntibodiesRecurrence

Stichwörter der Autor:innen

autoimmune thyroid diseasehyperthyroidismmethimazolepropylthiouracilrelapseremissionthyrotoxicosis

Substanzen

Antithyroid AgentsMethimazoleThyrotropinAntibodies

Autor:innen und Institutionen

  • Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Orthopaedics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Informatic Innovation Center of Excellence and School of Informatics, Walailak University, Nakhon Si Thammarat, Thailand.

ORCID-Profile: Pat Mahachoklertwattana, Preamrudee Poomthavorn

Zitieren

APA

Puttawong, D., Mahachoklertwattana, P., Numthavaj, P., Woratanarat, P., Pongratanakul, S., Koad, P., & Poomthavorn, P. (2023). Long‐term outcomes of anti‐thyroid drug treatment in childhood‐onset Graves' disease. Clinical Endocrinology. https://doi.org/10.1111/cen.14869

Vancouver

Puttawong D, Mahachoklertwattana P, Numthavaj P, Woratanarat P, Pongratanakul S, Koad P, et al. Long‐term outcomes of anti‐thyroid drug treatment in childhood‐onset Graves' disease. Clinical Endocrinology. 2023. doi:10.1111/cen.14869

BibTeX
@article{Puttawong2023,
  author = {Puttawong, Dolrutai and Mahachoklertwattana, Pat and Numthavaj, Pawin and Woratanarat, Patarawan and Pongratanakul, Sarunyu and Koad, Peeravit and Poomthavorn, Preamrudee},
  title = {Long‐term outcomes of anti‐thyroid drug treatment in childhood‐onset Graves' disease},
  journal = {Clinical Endocrinology},
  year = {2023},
  doi = {10.1111/cen.14869}
}
Kostenlos starten →